Fundraising Choices in Life Sciences – When and Why

January 7, 2022

LifeSci Partners Corporate Access Event
Panel: Fundraising Choices in Life Sciences – When and Why

Access to capital will always be the lifeblood of the biotech industry. Having a well-planned long-term equity financing strategy is arguably as important as an executive team’s approach to deploy that capital. More than ever before, savvy investors look for management teams with the financial acumen to navigate the capital markets in addition to their traditional analysis of a company’s pipeline fundamentals. Panelists will share their approach to the when and why of their fundraising choices.

Tom Rorke, LifeSci Advisors

Scott Struthers, CEO, Crinetics Pharmaceuticals, Inc.
Renee Aguiar-Lucande, CEO, Calliditas Therapeutics AB